292 related articles for article (PubMed ID: 1353135)
1. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
[TBL] [Abstract][Full Text] [Related]
2. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
3. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
[TBL] [Abstract][Full Text] [Related]
6. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.
Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
Psychol Med; 1993 Aug; 23(3):791-7. PubMed ID: 7901865
[TBL] [Abstract][Full Text] [Related]
8. SPECT technique for visualization of cerebral dopamine D2 receptors.
Konig P; Benzer MK; Fritzche H
Am J Psychiatry; 1991 Nov; 148(11):1607-8. PubMed ID: 1681752
[No Abstract] [Full Text] [Related]
9. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
10. Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia.
Geaney DP; Ellis PM; Soper N; Shepstone BJ; Cowen PJ
Biol Psychiatry; 1992 Aug; 32(3):293-5. PubMed ID: 1358229
[No Abstract] [Full Text] [Related]
11. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
[TBL] [Abstract][Full Text] [Related]
12. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
[TBL] [Abstract][Full Text] [Related]
13. [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
Künstler U; Hohdorf K; Regenthal R; Seese A; Gertz HJ
Nervenarzt; 2000 May; 71(5):373-9. PubMed ID: 10846712
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
[TBL] [Abstract][Full Text] [Related]
15. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
[TBL] [Abstract][Full Text] [Related]
16. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
17. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
[TBL] [Abstract][Full Text] [Related]
18. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
Wiesel FA; Farde L; Nordström AL; Sedvall G
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
[TBL] [Abstract][Full Text] [Related]
19. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
20. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
